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Abstract

Brain Regions Affected

Methods & Measurements

For years, the promise of psychedelics in therapeutic settings has been deterred by their

Measurements

Methods

general illegality. However, present day research shows promise in treating varying mental
disorders. Amongst these disorders is Post Traumatic Stress Disorder (PTSD). According to

•

Participants will include Veterans diagnosed with Post-Traumatic Stress Disorder (PTSD)

the organization, PTSD United, PTSD presently effects about eight percent of Americans.

•

Predicted Sample Size: 16

Measurements are official measures taken from U.S. Department of Veteran Affairs

•

Qualifications for Study:

Clinical-Administered PTSD Scale (CAPS)

Many of the current treatments only offer symptomatic relief and do not work for every

Participants must have served in the military.

case of PTSD. Psychedelics presently offer an alternative method of healing that focuses on

Participants must have score of 3 or higher on the CAPS scale.

treatment of the core issue with an emphasis on human connection and guided

Participants must not be undergoing any other forms of psychotherapy or drug

confrontation of emotions and/or trauma. Currently, it is one of the few PTSD-based
therapies that allows for physical contact in the form of comfort and solidarity in the human

•

Dissociative Subtype of PTSD Scale (DSPS)

Placebo-Group

Measures frequency on scale of 1-4 and severity on scale of 1-5
Difficulty Living and Working Environmental Scale (DDRI-2, Sec. C)
Score range from 14-70
Analytical Plan

•

Trained guides and therapists, one of each per participant, present during all sessions.

In order to analyze the individual results of each group and their relations to

•

Exposure-based psychotherapy aided by either MDMA, psilocybin, or placebo.

the three different scales, we will conduct a one-way ANOVA.

•

Three government-approved PTSD scale tests given before sessions and after periodically.

•

Safe and effect dosages given during session

MDMA is relatively low-risk in its pure state, especially at lower doses. (Parrott, 2013). MDMA reduces brain activity in the amygdala,

MDMA: between 75-125 mg

the area of the brain responsible for fear responses, suggesting that it may make revisitation of traumatic memories easier. (Thal &

Implications & Possible Limitations

Psilocybin: between 0.045 to 0.429 mg

Lommen, 2018). Studies addressing concerns of MDMA’s effects on long-term cognitive ability have found no difference between

•

Figure B

PTSD specifically affects the HPA axis, areas
of the limbic system (amygdala, hippocampus,
anterior cingulate), medial prefrontal cortex,
anterior cingulate, and the frontal lobe
MDMA specifically affects areas of the limbic
system (the left portion of the amygdala, basal
ganglia, hypothalamus, hippocampus) and the
Figure C
neocortex
Figure A: Brain Scan: PTSD Brain vs. Non-PTSD Brain
Psilocybin specifically affects the limbic
Figure B: Brain Scan MDMA
system (hippocampus, amygdala, thalmus) and
Figure C: Brain Scan: Psilocybin
the frontal/posterior cingulate/medial
prefrontal/occipital cortexes

lack of awareness, and psychogenic amnesia

MDMA-Group

help those struggling with PTSD.

Figure A

Includes three sub-scales focusing on PTSD symptoms of depersonalization,

Three consistent groups:

Psilocybin-Group

moderate-use participants’ and nondrug participants’ cognitive abilities. However, heavy-use participants exhibited a decrease in cognitive

Scale of 0-4 used to access level of severity of trauma

therapy while undergoing treatment in study.

connection. Presently, there is a need to further research into how psychedelic drugs can

Past Research
.

Measurements to be administered before and after treatment as well as during follow-up sessions.

Follow-up therapy sessions conducted after dose session

If the hypotheses are confirmed, this would add support to the already growing range of alternative treatment

abilities. (Garcia-Romeu & Kersgaard, 2016)

options involving psychedelics for patients suffering from PTSD. Furthermore, this treatment path would less

Doses between 50 and 75 mg were found to be both physically and psychologically safe for participants. (Bouso, Doblin, & al., 2008).

suppress symptoms, typical of most drugs used in the treatment of PTSD, and more help patients, in a safe setting

MDMA affects the left portion amygdala, allowing for participants to feel less anxious and fearful and allow them the ability to revisit

with a trained therapist, work through traumatic memories and the emotions associated with those memories. This in

traumatic memories and experiences without feeling previously mentioned emotions. (Bouso, Doblin, & al., 2008). A study done by

Guidelines

Bouso, Doblin, & al., using the Severity of Symptoms Scale for PTSD (SSSPTSD) which can be broken to assess symptoms of re-

return should allow patients with PTSD to have lowered scores on the CAPS, DSPS, and DDRI-2, Sec. C and

experiencing trauma, increased arousal in fear, avoidance, and somatic symptoms of anxiety, showed that a total mean of 41.5 out of 51

therefore a better quality of life. Overall, confirmed hypotheses should correlate with a breakthrough in the overall

overall on the scale with a score of 12.7 out of 15 relating to re-experiences, 11.7 out of 15 relating to increased arousal, 16.2 out of 21

treatment of PTSD.

relating to avoidance, and 24.5 out of 39 relating to somatic symptoms of anxiety. Post results of participants in the MDMA group scored

Possible limitations may include:

a mean of 28.3 out of 51 overall, 10 out of 15 relating to re-experiences, 6.6 out of 15 relating to increased arousal in fear, 11.6 out of 21
relating to avoidance, and 20 out of 39 relating to somatic symptoms of arousal. “....an overall remission rate of 66.2% and low rates of
adverse effects have been found in the six phase two trials conducted in clinical setting with 105 blinded subjects with chronic PTSD.”
(Thal & Lommen, 2018)

Guidelines for Treatment Sessions
Guidelines are taken from the Multidisciplinary Association for Psychedelics Studies (MAPS) provided guide for the use of MDMA in treatment of
PTSD.

Positive and negative traits can be attributed to personal mindset and overall setting before and after administration. (Tyls, Palenicek, &

•

A need for more research to be fully conducted before results are accepted

•

A limited sample size

•

Treatment may vary based on individual cases and may not work for all persons suffering from PTSD

•

There are legal implications that could slow further research

Horacek, 2014)The toxicity for psilocybin is low; the dosage require for an overdose is much higher than the psychoactive dosage

Citations

typically taken. (Tyls, Palenicek, & Horacek, 2014).
Psilocybin affects the hippocampus, temporarily suppressing the brain’s fear response. (Catlow, Song, Paredes, Kirstein, & SanchezRamos, 2013) Psilocybin reduces activity in the amygdala, associated with communicating fear and threat signals to the frontal cortex, in
return shifting from negative to positive valence. (Kraehenmann, Schmidt, & al., 2016). Psilocybin has also shown to allow for more
vivid memories. (Cahart-Harris, Leech, & al., 2012). Study comparing psilocybin and a placebo had a p-value of .004

Preparatory:

Trained professionals and
patient are mindful of the
role they are playing and
fully prepared to undergo
treatment session.

Setting properly prepared for
any possible needs of the
patient.

Dosage administered; short
session incorporated before
effects take place.

During:

Therapists are mindful of
their role as guides, listeners,
and caretakers for their
patients, maintaining a safe
space and reassurance.

Engage in breathing exercises
at the beginning of the onset
of the substance. Interaction
periods here should be
evenly engagement and selfexploratory.

During the peak effect, the
patient should be fully
engaged in self-exploration
and any trauma; typically
facing trauma precursors an
affirming experience.

Post &
Follow-Ups:

As effects wear, therapy
session may be conducted if
patient so wishes. This
session incorporates any
outside sources, such as a
significant other.

Any more substance-induced
sessions should be
conducted a few weeks after.

Weekly therapy sessions
should be conducted as well
as monthly physical checkups on-site. Post scores will
be taken during weekly
sessions.

Hypothesis
Will there be significant differences regarding the effects of MDMA and Psilocybin in the treatment of
PTSD? If so, which of these drugs will be the most beneficial?
Both MDMA and psilocybin affect areas of the brain associated with fear response. Therefore, the usage of
these drugs should help alleviate stress and anxiety as well as any corresponding symptoms associated with
the re-visitation of painful memories, making it easier for participants to work through these memories with
trained therapists than participants who are given a dose of placebo.
We predict that, consistent with prior research, that there will be a significant difference (p<0.001) between
the placebo group and MDMA and psilocybin groups in terms of continuing improvement in scores and
remission rates.
Participants who are given MDMA should show higher improvement relating to PTSD symptoms than
those given psilocybin. However, those given psilocybin should still show higher improvement than those
given a placebo.

B. (2017, August 29). MDMA [Skeletal structure of an MDMA molecule.]. Retrieved from https://psychonautwiki.org/wiki/File:MDMA.svg
Bouso, J. C., Doblin, R., Farré, M., Alcázar, M. Á, & Gómez-Jarabo, G. (2008). MDMA-Assisted Psychotherapy Using Low Doses in a
Small Sample of Women with Chronic Posttraumatic Stress Disorder. Journal of Psychoactive Drugs,40(3), 225-236.
doi:10.1080/02791072.2008.10400637
[Brain activity under psilocybin with a decrease (blue) in evolutionary advanced brain regions and an increase (orange) in memory and emotion
centres.]. (n.d.). Retrieved from https://www.sciencedaily.com/releases/2014/07/140703102649.htm Credit: Imperial College London
Carhart-Harris, R. (n.d.). [Brain Regions Effected by MDMA]. Retrieved from https://www.imperial.ac.uk/news/image/mainnews2012/20800.jpg
Carhart-Harris, R., Leech, R., Williams, T., Erritzoe, D., Abbasi, N., Bargiotas, T., . . . Nutt, D. (2012). Implications for
psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. British Journal of Psychiatry, 200(3), 238-244.
doi:10.1192/bjp.bp.111.103309
Catlow, B., Song, J., Paredes, S., Kirstein, D., & Sanchez-Ramos, A. (2013). Effects of psilocybin on hippocampal neurogenesis and
extinction of trace fear conditioning. Experimental Brain Research., 228(4), 481-491. DOI 10.1007/s00221-013-3579-0
Garcia-Romeu, A., Kersgaard, B., & Addy, P. (2016). Clinical applications of hallucinogens: A review. Experimental and Clinical
Psychopharmacology, 24(4), 229. DOI: 10.1037/pha0000084.
Kraehenmann, R., Schmidt, A., Friston, K., Preller, K. H., Seifritz, E., & Vollenweider, F. X. (2016). The mixed serotonin receptor agonist
psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage: Clinical,11, 53-60. doi:10.1016/j.nicl.2015.08.009
Hathaway, B. (2017, July 17). [PET
news.yale.edu/sites/default/files/styles/horizontal_image/public/ptsd_0.jpg?itok=0EClM8Vy&c=8acb728cf74d3ff47d07477352e09341
MillerJan, G., VogelMay, G., WadmanMay, M., KaiserMay, J., MervisMay, J., & MervisMay, J. (2017, December 10). Mapping the Psychedelic
Brain. Retrieved from https://www.sciencemag.org/news/2012/01/mapping-psychedelic-brain
Scan Comparisons PTSD]. Retrieved from https://Mithoefer, M. C., M.D. (2015, August 19). A Manual for MDMA-Assisted Psychotherapy in the
Treatment of Posttraumatic Stress Disorder. Retrieved from http://www.maps.org/research-archive/mdma/MDMA-Assisted-PsychotherapyTreatment-Manual-Version7-19Aug15-FINAL.pdf
Mithoefer, M. C., Grob, C. S., & Brewerton, T. D. (2016). Novel psychopharmacological therapies for psychiatric disorders: Psilocybin
and MDMA. The Lancet Psychiatry, 3(5), 481-488. doi:10.1016/s2215-0366(15)00576-3
National Institute on Drug Abuse. (n.d.). 6: Brain areas sensitive to ecstasy. Retrieved from https://www.drugabuse.gov/publications/teachingpackets/neurobiology-ecstasy/section-i/6-brain-areas-sensitive-to-ecstasy
Parrott, A. (2013). Human psychobiology of MDMA or ‘ecstasy’: An overview of 25 years of empirical research. Human
Psychopharmacology Clinical and Experimental., 28(4), 289. DOI: 10.1002/hup.2318
Psilocy [Psilocybin Chemical]. (n.d.). Retrieved from http://www.ch.ic.ac.uk/rzepa/mim/drugs/html/psilocybin.htm
PTSD: National Center for PTSD. (2010, July 14). Retrieved from https://www.ptsd.va.gov/professional/assessment/all_measures.asp
PTSD Statistics. (n.d.). Retrieved from http://www.ptsdunited.org/ptsd-statistics-2/
Rupp, M. (2017, May 31). Synapse-MDMA [Digital image]. Retrieved from https://sapiensoup.com/images/serotonin/synapse-MDMA@2x.png
Sherin, J. E., & Nemeroff, C. B. (2011, September). Post-traumatic stress disorder: The neurobiological impact of psychological trauma. Retrieved
from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182008/
Thal, S., & Lommen, M. (2018). Correction to: Current perspective on mdma-assisted psychotherapy for posttraumatic stress
disorder. Journal of Contemporary Psychotherapy., 48(99), 108. DOI: 10.107/s10879-017-9379-2
Tylš, F., Páleníček, T., & Horáček, J. (2014). Psilocybin—Summary of knowledge and new perspectives. European
Neuropsychopharmacology., 24(3), 342. DOI: 10.1016/j.euroneuro.2013.12.006

